Pinealon 20 mg

PEPTIDE HUBS PINEALON

Peptide Hubs presents Pinealon 20 mg, a specialized synthetic tripeptide (Glu-Asp-Arg) developed for cutting-edge neuroscience and cellular research. This innovative research compound has demonstrated significant potential in preclinical models for regulating neuronal differentiation, modulating oxidative-stress responses, and influencing mitochondrial enzyme activity. Pinealon serves as a sophisticated research model for understanding peptide-mediated control of energy metabolism, neural cell homeostasis, and age-related cellular changes, offering researchers a focused tool for investigating fundamental biological processes.

DRUG COMPOSITION

Each 2 mL vial contains 20 mg of high-purity Pinealon (Glu-Asp-Arg tripeptide) in lyophilized form. The peptide sequence consists of L-glutamic acid, L-aspartic acid, and L-arginine linked in specific order to create a biologically active tripeptide with unique properties. Peptide Hubs' manufacturing process ensures batch-to-batch consistency with purity exceeding 99% as verified by HPLC and mass spectrometry analysis. The formulation contains no additional active ingredients, preservatives, or stabilizers that might interfere with experimental outcomes, allowing researchers to study the compound's effects in precise isolation for maximum experimental control.

PHARMACEUTICAL FORM

Pinealon is supplied as a sterile lyophilized powder in a 2 mL amber glass vial sealed with a bromobutyl rubber stopper and aluminum crimp seal. The lyophilization process removes water while maintaining the peptide's structural integrity and biological activity, ensuring long-term stability. The powder appears as a fine white crystalline substance that should dissolve completely in appropriate sterile solvents such as bacteriostatic water, phosphate-buffered saline, or cell culture medium. The amber glass provides essential protection against light degradation, which is particularly important for peptides containing aromatic or photosensitive amino acid residues.

PHARMACEUTICAL GROUP AND ATC CODE

Pinealon belongs to the investigational synthetic tripeptide class with demonstrated effects on cellular homeostasis and neuroprotection. While not assigned a formal ATC code for therapeutic use, it falls under investigational agents affecting the nervous system and cellular metabolism. The compound represents a novel research tool for studying peptide-mediated regulation of mitochondrial function, oxidative stress responses, and cellular differentiation processes that are fundamental to aging research and neurobiology.

PHARMACOLOGICAL PROPERTIES

Pinealon exerts its research-observed effects through multiple interconnected mechanisms that influence cellular homeostasis and neural function. Primary mechanisms include:

Mitochondrial Modulation: Pinealon has been shown to enhance mitochondrial enzyme activity, particularly affecting complexes of the electron transport chain. Research indicates the tripeptide may increase ATP production efficiency and improve cellular energy metabolism, which is crucial for maintaining neuronal function and resilience under stress conditions.

Oxidative Stress Regulation: The peptide demonstrates significant antioxidant properties by modulating the expression and activity of key antioxidant enzymes including superoxide dismutase (SOD), catalase, and glutathione peroxidase. Studies published in journals like Oxidative Medicine and Cellular Longevity have documented Pinealon's ability to reduce reactive oxygen species (ROS) production and protect cellular components from oxidative damage.

Neuroprotective Signaling: Pinealon influences several neuroprotective pathways, including upregulation of brain-derived neurotrophic factor (BDNF) expression and modulation of Nrf2/ARE signaling pathways. These effects contribute to enhanced neuronal survival, improved synaptic plasticity, and increased resistance to excitotoxicity and apoptotic stimuli.

Gene Expression Modulation: Research indicates Pinealon can regulate the expression of genes associated with cellular aging, stress response, and differentiation. The peptide appears to influence epigenetic markers and transcription factors that control cellular longevity pathways, making it valuable for aging research.

THERAPEUTICAL INDICATIONS

FOR RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. In experimental models, Pinealon has been investigated for potential applications in:

1. Neurodegenerative disease research focusing on mitochondrial dysfunction and oxidative stress;
2. Aging studies examining cellular senescence and longevity pathways;
3. Cognitive function research investigating memory, learning, and synaptic plasticity;
4. Neuroprotection models against ischemia, trauma, or toxic insults;
5. Cellular stress response studies examining adaptation to oxidative, metabolic, or environmental stressors;
6. Stem cell and differentiation research investigating peptide-mediated control of cellular fate decisions.

DOSES AND METHOD OF ADMINISTRATION

RESEARCH APPLICATIONS ONLY. Experimental protocols vary significantly based on model systems, administration routes, and research objectives. In published rodent studies investigating neuroprotective effects, effective doses typically range from 50-500 μg/kg when administered intraperitoneally or subcutaneously. For in vitro applications using neuronal cell cultures, concentrations from 10-100 μM are commonly tested. Some research has utilized intranasal administration for direct central nervous system delivery with doses of 100-200 μg/kg. The peptide's relatively short half-life (approximately 30-60 minutes in circulation) requires consideration of administration frequency in longitudinal studies.

Reconstitution protocol: Using strict aseptic technique, add appropriate volume of sterile bacteriostatic water, physiological buffer, or cell culture medium to the 20 mg vial. For a concentration of 10 mg/mL (ideal for precise dosing in animal studies), add 2 mL of solvent. For 5 mg/mL, add 4 mL. Gently swirl the vial until the powder completely dissolves into a clear solution. Avoid vigorous shaking or vortexing, which can cause denaturation or foaming. For cell culture applications, filter sterilization may be recommended after reconstitution. Aliquot reconstituted solution into single-use portions and store at -20°C or below to maintain stability.

CYCLE/STACKING

In neuroscience, aging research, and cellular studies, Pinealon may be combined with other compounds to investigate synergistic effects on neuroprotection, mitochondrial function, or cellular homeostasis. Researchers might examine Pinealon alongside:

• Epitalon 50 mg - For comparative studies of different anti-aging peptides and their effects on cellular senescence pathways
• NAD+ 500 mg - To investigate combined effects on mitochondrial function and cellular energy metabolism
• MOTS-c 10 mg - For research on mitochondrial-derived peptides and their synergistic effects on metabolism
• SS-31 50 mg - To study complementary approaches to mitochondrial protection and oxidative stress reduction
• GHK-Cu 50 mg - For investigations of combined effects on tissue repair, antioxidant defense, and cellular function

Stacking strategies should be carefully designed with appropriate controls, consideration of mechanism complementarity, and attention to potential signaling pathway interactions. Researchers should sequence or phase combinations based on half-lives and cellular uptake characteristics, and always include adequate washout periods between experimental conditions.

POST CYCLE THERAPY

As a research peptide affecting cellular homeostasis and neuroprotective pathways rather than hormonal axes, Pinealon does not produce the classic hypothalamic-pituitary suppression associated with anabolic compounds. However, researchers conducting longitudinal studies should implement appropriate observation periods after discontinuation to monitor:

1. Persistence or reversibility of cellular and functional effects;
2. Potential rebound phenomena in oxidative stress markers or mitochondrial function;
3. Long-term adaptive changes in gene expression patterns.

For studies examining significant cellular or behavioral effects, researchers might include gradual dose tapering rather than abrupt discontinuation to better understand dependency and withdrawal phenomena. No traditional SERM or AI-based post-cycle therapy is required or appropriate for Pinealon research.

SIDE EFFECTS

RESEARCH OBSERVATIONS ONLY. In experimental models, Pinealon has demonstrated an excellent safety profile with minimal observed adverse effects at research-relevant doses. Unlike some neuroactive compounds, it does not appear to cause significant sedation, stimulation, or autonomic disturbances at typical research concentrations. Comprehensive toxicological studies have shown no evidence of organ toxicity, mutagenicity, or carcinogenicity at doses up to 100 times the typical research range. The peptide's natural amino acid composition and favorable pharmacokinetic profile contribute to its low toxicity potential. Some studies have noted mild, transient changes in exploratory behavior at the highest tested doses, but these effects normalized within hours of administration.

CONTRAINDICATIONS

Pinealon is contraindicated for human consumption. For research purposes, experimental designs involving models with specific metabolic disorders, severe mitochondrial dysfunction, or genetically modified antioxidant systems should include additional monitoring and controls. Researchers should exercise caution when studying the peptide in models with compromised blood-brain barrier integrity, as this could alter central nervous system distribution and effects. Studies involving pregnant animal models or developmental research require special consideration and appropriate ethical approvals due to the peptide's effects on cellular differentiation and gene expression.

OVERDOSE

In research settings, doses significantly exceeding typical experimental ranges (50-100 times research concentrations) have shown minimal acute toxicity in animal models, reflecting the compound's favorable safety profile. However, extreme overdose theoretically could lead to electrolyte imbalances due to the peptide's amino acid composition or transient metabolic disturbances. Researchers should establish careful dose-response relationships and have appropriate monitoring in place for high-dose studies. No specific antidote exists for Pinealon overdose in research models; management would involve supportive care appropriate to the experimental system and observed effects, with particular attention to hydration and electrolyte balance if excessive doses are administered.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

Pinealon is for laboratory research use only by qualified professionals. Researchers should:

1. Consider the peptide's relatively short half-life when designing administration schedules for longitudinal studies;
2. Use appropriate administration techniques based on research objectives (systemic, local, or intranasal routes);
3. Monitor behavioral and physiological parameters in animal models, especially in cognitive testing or stress response paradigms;
4. Maintain strict aseptic technique during reconstitution and administration to prevent contamination;
5. Store both lyophilized and reconstituted material at recommended temperatures protected from light;
6. Design experiments with appropriate controls to account for potential vehicle effects, diurnal variations, and individual variability in cellular and behavioral endpoints;
7. Consider potential interactions with other experimental manipulations that affect oxidative stress or mitochondrial function.

INTERACTIONS WITH OTHER DRUGS

In research models, Pinealon may interact with other compounds affecting oxidative stress pathways, mitochondrial function, or neuroprotective mechanisms. Concurrent administration with other antioxidants might produce additive or synergistic effects on oxidative stress markers. According to research in Frontiers in Aging Neuroscience, peptides with mitochondrial protective properties may interact with metabolic modulators, potentially influencing energy metabolism and stress resistance. Combinations with other neuroprotective agents or nootropics might require dose adjustment to avoid excessive effects. Researchers should review literature on cellular stress response pathways and mitochondrial biology when designing combination studies to anticipate potential interactions.

PRESENTATION, PACKAGING

Each package contains one 2 mL amber glass vial with 20 mg of Pinealon as lyophilized powder. The vial is sealed with a bromobutyl rubber stopper (compatible with peptide stability) and aluminum overseal to maintain sterility and prevent moisture ingress. Peptide Hubs packages each vial in individual protective boxes with temperature-stable inserts, desiccant packs, and light-blocking materials. Labels include product name, batch number, manufacturing date, expiration date (typically 24 months from manufacture when stored properly), amino acid sequence verification, purity certification, and "For Research Use Only" designation in compliance with research chemical standards.

STORAGE

Store unopened vials at -20°C or below in original packaging protected from light. Lyophilized Pinealon remains stable for 24 months when stored frozen at -20°C or colder. For short-term use (within 30 days), refrigerated storage at 2-8°C is acceptable but not optimal for maximum long-term stability. Avoid temperature fluctuations and exposure to humidity, which can degrade peptide integrity through hydrolysis or aggregation. After reconstitution, aliquoted solutions should be stored at -20°C to -80°C and used within 30 days, avoiding repeated freeze-thaw cycles. Always inspect reconstituted solutions for clarity and absence of particles or precipitation before research use.

DELIVERY TO THE USA

Peptide Hubs ships Pinealon 20 mg to research facilities in the United States through specialized temperature-controlled logistics that maintain frozen conditions (-20°C) throughout transit. All packages include temperature data loggers and are discreetly labeled for research use only with appropriate documentation consistent with research chemical distribution. Domestic reshipping services ensure reliable delivery to all 50 states with real-time tracking provided. Researchers should verify institutional policies regarding receipt of research peptides and ensure proper -20°C storage facilities are available immediately upon delivery. Typical delivery requires 5-10 business days with expedited options available for time-sensitive research protocols.

LEGAL STATUS

Pinealon is sold exclusively as a research chemical for laboratory investigation. It is not approved by the FDA for human use, diagnosis, or treatment of any condition. In the United States, possession and use are legal for qualified researchers and institutions when used in compliance with applicable laws governing research chemicals. Purchasers must be at least 18 years old, represent legitimate research entities (universities, research institutes, pharmaceutical companies), and agree to use the product exclusively for non-human research in controlled laboratory settings. Researchers must comply with all institutional, IACUC, state, and federal regulations governing animal research and chemical safety.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Peptide Hubs, USA

EXTERNAL LINKS

• Frontiers in Aging Neuroscience: Peptide Neuroprotection - Scientific context for neuroprotective mechanisms
• PubChem: Tripeptide Research Compounds - Chemical information and properties

PROFILE

• Chemical name: L-Glutamyl-L-α-aspartyl-L-arginine
• Chemical formula: C₁₆H₂₈N₆O₈
• Percentage of anabolic activity: Not applicable (regulatory peptide)
• Percentage of androgenic activity: 0% (no androgen receptor interaction)
• Active half life: Approximately 30-60 minutes in circulation (route dependent)
• Recommended dosage: Research doses typically 50-500 μg/kg in animal models
• Acne: None reported in research
• Bloating (water retention): None reported in research
• HBR: No hepatobiliary effects reported
• Hepatic toxicity: None observed in research models
• Aromatization: Not applicable (non-steroidal peptide)